Alzheimer's and Dementia: Translational Research and Clinical Interventions
ESCI-ISI SCOPUS (2015-2025)
2352-8737
Mỹ
Cơ quản chủ quản: WILEY , John Wiley & Sons Inc.
Lĩnh vực:
Psychiatry and Mental HealthNeurology (clinical)
Phân tích ảnh hưởng
Các bài báo tiêu biểu
Inflammation as a central mechanism in Alzheimer's disease
Tập 4 Số 1 - Trang 575-590 - 2018
AbstractAlzheimer's disease (AD) is a progressive neurodegenerative disorder
that is characterized by cognitive decline and the presence of two core
pathologies, amyloid β plaques and neurofibrillary tangles. Over the last
decade, the presence of a sustained immune response in the brain has emerged as
a third core pathology in AD. The sustained activation of the brain's resident
macrophages (micro...
Alzheimer's disease drug development pipeline: 2018
Tập 4 Số 1 - Trang 195-214 - 2018
AbstractIntroductionTreatments for Alzheimer's disease (AD) are needed due to
the growing number of individuals with preclinical, prodromal, and dementia
forms of AD. Drug development for AD therapies can be examined by inspecting the
drug development pipeline as represented on
clinicaltrials.gov.MethodsClinicaltrials.gov was assessed as of January 30, 2018
to determine AD therapies represented in...
Alzheimer's disease drug development pipeline: 2017
Tập 3 Số 3 - Trang 367-384 - 2017
AbstractIntroductionThere is an urgent need to develop new treatments for
Alzheimer's disease (AD) and to understand the drug development process for new
AD therapies.MethodsWe assessed the agents in the AD pipeline as documented in
clinicaltrials.gov for phase I, phase II, and phase III, accessed
1/5/2017.ResultsThere are 105 agents in the AD treatment development pipeline,
of which 25 agents are...
Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health
Tập 3 Số 3 - Trang 291-300 - 2017
AbstractCognitive decline leading to dementia represents a global health burden.
In the absence of targeted pharmacotherapy, lifestyle approaches remain the best
option for slowing the onset of dementia. However, older adults spend very
little time doing moderate to vigorous exercise and spend a majority of time in
sedentary behavior. Sedentary behavior has been linked to poor glycemic control
and...
Amyloid‐associated increases in longitudinal report of subjective cognitive complaints
Tập 4 - Trang 444-449 - 2018
AbstractIntroductionTo investigate whether baseline subjective cognitive
complaints (SCCs) predict longitudinal decline on neuropsychological testing and
whether SCC increases longitudinally, in the setting of high levels of amyloid
burden.MethodsTwo hundred seventy‐nine clinically normal older participants
(mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of
community‐dwe...
Accelerating drug development for Alzheimer's disease through the use of data standards
Tập 3 - Trang 273-283 - 2017
AbstractIntroductionThe exceedingly high rate of failed trials in Alzheimer's
disease (AD) calls for immediate attention to improve efficiencies and learning
from past, ongoing, and future trials. Accurate, highly rigorous standardized
data are at the core of meaningful scientific research. Data standards allow for
proper integration of clinical data sets and represent the essential foundation
for...
Technology for home dementia care: A prototype locating system put to the test
Tập 3 - Trang 332-338 - 2017
AbstractIntroductionThe user experience of persons with dementia and their
primary caregivers with locating systems is not firmly
established.MethodsEighteen dyads used a prototype locating system during 4
weeks. Primary outcome measures were ratings of usability, and product functions
and features. Secondary outcome measures were caregiver burden, perceived
self‐efficacy, frequency of use, and wi...
Multiple‐dose ponezumab for mild‐to‐moderate Alzheimer's disease: Safety and efficacy
Tập 3 - Trang 339-347 - 2017
AbstractIntroductionMultiple intravenous doses of ponezumab, an anti‐amyloid
antibody, were evaluated in subjects with mild‐to‐moderate Alzheimer's disease
(AD).MethodsIn part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or
1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were
randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo.
Subjects rec...
Web‐enabled conversational interactions as a method to improve cognitive functions: Results of a 6‐week randomized controlled trial
Tập 1 - Trang 1-12 - 2015
AbstractIntroductionIncreasing social interaction could be a promising
intervention for improving cognitive function. We examined the feasibility of a
randomized controlled trial to assess whether conversation‐based cognitive
stimulation through personal computers, webcams, and a user‐friendly interactive
Internet interface had high adherence and a positive effect on cognitive
function among older...
Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial
Tập 1 - Trang 95-102 - 2015
AbstractIntroductionWe conducted a phase 1 clinical trial in nine patients with
mild‐to‐moderate Alzheimer's disease to evaluate the safety and dose‐limiting
toxicity of stereotactic brain injection of human umbilical cord blood–derived
mesenchymal stem cells (hUCB‐MSCs).MethodsThe low‐ (n = 3) and high‐dose (n = 6)
groups received a total of 3.0 × 106 cells/60 μL and 6.0 × 106 cells/60 μL,
respec...